There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Elevance Health (ELV – Research Report) and Cogent Biosciences (COGT – Research Report) with bullish sentiments.
Elevance Health (ELV)
Wells Fargo analyst Steve Baxter maintained a Buy rating on Elevance Health today and set a price target of $561.00. The company’s shares closed last Wednesday at $506.11, close to its 52-week high of $513.23.
According to TipRanks.com, Baxter is a 3-star analyst with an average return of
Currently, the analyst consensus on Elevance Health is a Strong Buy with an average price target of $569.11, implying a 12.6% upside from current levels. In a report released today, Bank of America Securities also maintained a Buy rating on the stock with a $580.00 price target.
See the top stocks recommended by analysts >>
Cogent Biosciences (COGT)
Citi analyst David Lebovitz reiterated a Buy rating on Cogent Biosciences today and set a price target of $11.00. The company’s shares closed last Wednesday at $8.70.
According to TipRanks.com, Lebovitz is a 2-star analyst with an average return of
Currently, the analyst consensus on Cogent Biosciences is a Strong Buy with an average price target of $14.00, which is a 63.7% upside from current levels. In a report issued on February 12, Needham also maintained a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ELV:
- Elevance Health Declares Quarterly Dividend for Shareholders
- Elevance Health (NYSE:ELV) Jumps after Exceeding Q4 Estimates
- Elevance Health reports Medical membership totaled ~47M at Dec. 31, 2023
- Elevance Health raises quarterly dividend 10.1% to $1.63 per share
- Elevance Health sees FY24 adjusted EPS ‘greater than’ $37.10, consensus $37.05
